The cut off value for diagnose significant fibrosis by 12 non-
Conditions
Interventions
Non invasive test such as
Fibroscan
Fibrotest
ElF test
M2BPGI
Fibrometer
Basic Lab
Experimental No treatment
Non invasive test
Sponsors
Srinagarind hospital Khon Kaen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Description of subjects and main criteria for inclusion • Patients age 18-65 in the Srinagarind Hospital between years 2016-2018 and receive a diagnosis viral hepatitis B or C infection or non-alcoholic steatohepatitis (NASH) one only. • ECOG performance status 0-1 • Patients must not treat with Peginterferon alfa (type 2a / 2b) in combination with Ribavirin before. • Stop drinking alcohol more than six months. • Child-Pugh score <= 6 • If cancer patients must undergo treatment to cure (curative aim) and disease-free period exceeding six months. • Volunteers participated in the research.
Exclusion criteria
Exclusion criteria: Description of main exclusion criteria • Patients with HIV co-infection. • Patients with contraindications to liver biopsy: patients do not cooperate, patients with risk bleeding cannot be solved by providing blood components (INR> 1.5 platelet <80,000). , Patients with skin infections in the ribs, Patients with obstructive jaundice, Patients with ascites, Patients suspected liver nodules. • Patients with uncontrolled underlying diseases, such as heart failure, renal failure, diabetes, hyper or hypothyroidism, hypertension, ischemic heart diseases, COPD, major depressive disorder. • Patients do not stop antiplatelet at least 10 days. • Pregnancy. • Organ transplant. • Patients during chemotherapy. • Patients with acute hemolysis or extra hepatic cholestasis. • Patients with chronic hemolysis or Gilbert's syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cut point non invasive test at the beginning of study Fibrotest fibrometer elf fibroscan fibrometer and lab | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic performance of non invasive test at the beginning of study Sensitivity specificity PPV NPV AUROC | — |
Countries
Thailand
Contacts
Public ContactWattana Sukeepaisarnjaroen
Outcome results
None listed